Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT07126158
Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
- NCT07126158 ↗
- Recruiting
- Washington University School of Medicine
- Focused
We haven't built an HCP commentary report on NCT07126158 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT07126158 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Phase II Study of Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Pancreatic Adenocarcinoma; Cancer of the Pancreas; Pancreas Cancer; Pancreatic Cancer
- Interventions
- Stereotactic body radiotherapy; Defactinib; Avutometinib
- Arms
- Experimental Arm: SBRT + Defactinib + Avutometinib · Experimental
- Control Arm: SBRT · Active comparator
- Enrollment
- 36 (estimated)
- Primary outcomes
- Progression-free survival (PFS) - Experimental Arm Only
- Sponsor
- Washington University School of Medicine with Verastem, Inc., The Foundation for Barnes-Jewish Hospital
- Start
- Apr 10, 2026
- Primary completion
- Apr 30, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT07126158 · updated Apr 15, 2026